Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and/or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Patients With Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function

Slide: 9 of 29

Guidelines for the Use of ACEIs, ARBs, or Both to Treat Patients With Cardiac Disease (2)

To determine if the same benefits seen with ACEIs and ARBs will extend to patients without heart failure or LVSD, trials have been conducted to evaluate the use of ACEIs and ARBs — alone or in combination — in patients who have stable ischemic heart disease and preserved LVSD. Previous systematic reviews have not included recent ACEI trials conducted in this population. Additionally, no systematic review has evaluated ARB therapy or  ACEI and ARB combination therapy in this population. From this body of evidence, the benefits and harms associated with the use of these therapies in this population of patients may be discerned.